Personalis (NASDAQ:PSNL) PT Lowered to $35.00 at Morgan Stanley

Personalis (NASDAQ:PSNL) had its price objective trimmed by Morgan Stanley from $38.00 to $35.00 in a report issued on Thursday, Benzinga reports. The firm currently has an overweight rating on the stock.

Several other brokerages have also commented on PSNL. HC Wainwright increased their price target on shares of Personalis from $30.00 to $50.00 and gave the stock a buy rating in a research note on Wednesday, January 13th. Truist began coverage on shares of Personalis in a research note on Wednesday, January 27th. They issued a buy rating and a $50.00 target price on the stock. Oppenheimer upgraded shares of Personalis from a market perform rating to an outperform rating and set a $28.00 target price on the stock in a research note on Wednesday, May 12th. Finally, Needham & Company LLC lowered their target price on shares of Personalis from $38.00 to $33.00 and set a buy rating on the stock in a research note on Wednesday, May 12th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average target price of $35.50.

Personalis stock opened at $19.74 on Thursday. The firm has a market cap of $866.74 million, a PE ratio of -18.62 and a beta of 1.71. The firm’s 50 day moving average price is $22.77 and its two-hundred day moving average price is $31.17. Personalis has a twelve month low of $10.09 and a twelve month high of $53.46.

Personalis (NASDAQ:PSNL) last released its quarterly earnings data on Wednesday, May 5th. The company reported ($0.29) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.37) by $0.08. Personalis had a negative net margin of 45.13% and a negative return on equity of 27.53%. Research analysts expect that Personalis will post -1.13 EPS for the current fiscal year.

In related news, CFO Aaron Tachibana sold 2,446 shares of Personalis stock in a transaction dated Wednesday, March 17th. The shares were sold at an average price of $26.73, for a total transaction of $65,381.58. Following the completion of the transaction, the chief financial officer now directly owns 167,823 shares of the company’s stock, valued at approximately $4,485,908.79. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Richard Chen sold 1,130 shares of Personalis stock in a transaction dated Wednesday, March 17th. The shares were sold at an average price of $26.73, for a total transaction of $30,204.90. Following the transaction, the insider now directly owns 83,317 shares of the company’s stock, valued at $2,227,063.41. The disclosure for this sale can be found here. Insiders have sold a total of 46,943 shares of company stock valued at $1,232,951 over the last ninety days. 8.20% of the stock is owned by insiders.

A number of hedge funds have recently made changes to their positions in the stock. Penserra Capital Management LLC lifted its holdings in Personalis by 171.2% during the 4th quarter. Penserra Capital Management LLC now owns 895 shares of the company’s stock valued at $32,000 after purchasing an additional 565 shares during the last quarter. Banque Cantonale Vaudoise increased its position in Personalis by 66.7% in the 1st quarter. Banque Cantonale Vaudoise now owns 1,500 shares of the company’s stock valued at $37,000 after acquiring an additional 600 shares in the last quarter. NEXT Financial Group Inc acquired a new stake in Personalis in the 4th quarter valued at about $25,000. AdvisorNet Financial Inc acquired a new stake in Personalis in the 4th quarter valued at about $27,000. Finally, Rhumbline Advisers increased its position in Personalis by 3.3% in the 1st quarter. Rhumbline Advisers now owns 25,554 shares of the company’s stock valued at $629,000 after acquiring an additional 818 shares in the last quarter. 65.46% of the stock is owned by hedge funds and other institutional investors.

About Personalis

Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics.

Recommended Story: Most Active Stocks

Analyst Recommendations for Personalis (NASDAQ:PSNL)

Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.